Skip to main content
Premium Trial:

Request an Annual Quote

PredictImmune Expands Licensing Deal With Cambridge Enterprise

NEW YORK – PredictImmune announced today an expansion of a worldwide licensing agreement to allow the UK firm first right of refusal to new technologies from Cambridge Enterprise.

The expanded deal grants PredictImmune right of first refusal to technology allowing for the prediction of disease outcome for systemic lupus erythematosus as a follow-on disease, the Cambridge, UK-based company said. A prior deal between the partners covered technology related to the prediction of disease outcome in relapsing-remitting autoimmune and inflammatory disease, specifically for inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

PredictImmune added that the new terms will allow the company to "evolve" its product line and hasten its products into this new therapeutic space.

Financial and other details of the deal were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.